Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies
The Journal of Clinical Pharmacology · 2026-01 · 66 (1)
DOI: 10.1002/jcph.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 27.09.2025. Verfasst von Hazel J Hunt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Corcept Therapeutics Incorporated, Redwood City, CA, USA. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis. Its overall pharmacokinetic characteristics were assessed, including its disposition (absorption, distribution, metabolism, and elimination [ADME]) and drug–drug interaction (DDI) potential. In vitro, miricorilant (1) demonstrated >99% plasma protein binding in mice, rats, monkeys, and humans, (2) was a modest inhibitor of CYP3A4, CYP2C8, CYP2C9, UGT1A1, and a strong inhibitor of BCRP, (3) was predominantly metabolized by CYP2C19 (≈94%), and (4) showed no induction potential for CYP1A2 and CYP2B6, but showed a concentration‐dependent induction of CYP3A4 (6.5‐fold) in 1 out of 3 donors tested. In a tissue distribution study in mice, miricorilant was distributed with high levels of radioactivity present in several tissues, including the liver. In animal and human ADME studies, the majority of total radioactivity was recovered in feces (>78%) versus urine (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Corcept Therapeutics Incorporated, Redwood City, CA, USA.
- Jade Consultants (Cambridge) Ltd., Cambridge, UK.
Zitieren
APA
Hunt, H. J., Donaldson, K. M., Kunta, J. R., & Custodio, J. M. (2026). Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies. The Journal of Clinical Pharmacology, 66(1). https://doi.org/10.1002/jcph.70113
Vancouver
Hunt HJ, Donaldson KM, Kunta JR, Custodio JM. Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies. The Journal of Clinical Pharmacology. 2026;66(1). doi:10.1002/jcph.70113
BibTeX
@article{Hunt2026,
author = {Hunt, Hazel J and Donaldson, Kirsteen M and Kunta, Jeevan R and Custodio, Joseph M},
title = {Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {1},
doi = {10.1002/jcph.70113}
}
EUVIMED